(NASDAQ:GILD) in a report issued on Sunday, April 23rd. The firm owned 25,694 shares of the biopharmaceutical company's stock after buying an additional 99 shares during the period. Highland Capital Management LLC's holdings …
In this article we will analyse the latest data and future performance of this growth …
Wall Street
Whitehouse and his wife bought additional stock in Gilead and Amgen on Nov. 28, two days before the House voted on the bill. The day President Barack Obama …
stock trading
The decreasing revenue of Gilead’s HCV franchise may impact the stock prices of the Vanguard S&P 500 ETF (VOO). Gilead makes up about 0.42% of VOO’s total portfolio holdings.
Estimize has Gilead earning more, or $6.72 billion. Stock reaction: Gilead
Gilead
Gilead Sciences, Inc. (NASDAQ:GILD) shares are getting whacked following weaker-than-expected earnings. The biopharmaceutical company reported earnings of $2.23 per share and revenues of $6.5 billion. Both fell short of analyst …
Q1
Gilead Sciences, Inc. (NASDAQ:GILD) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Friday, May 5th. According to Zacks, “Although Gilead’s first-quarter results beat …
Gilead Sciences, Inc. (NASDAQ:GILD) stock is a heavyweight in the biotech space; the company bolsters a $105.0-billion market cap and ranks high among its competitors like GlaxoSmithKline plc (NYSE:GSK) and Pfizer Inc. …
Gilead Sciences Inc. (Nasdaq: GILD) stock hit a 52-week high of $92.97 this morning (Thursday) after the company crushed earnings estimates last night. At that price, GILD stock has climbed 3% from yesterday's close. In …
NASDAQ
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing …
ZACKS4mon
Investor